From the molecule to the clinic - inhibiting HER2 to treat breast cancer.

被引：49

作者：

Eisenhauer, EA ^{[1
]}

机构：

[1] Queens Univ, Kingston, ON K7L 3N6, Canada

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2001年 / 344卷 / 11期

关键词：

D O I：

10.1056/NEJM200103153441110

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：841 / 842

页数：2

共 14 条

[1] HUMANIZATION OF AN ANTI-P185HER2 ANTIBODY FOR HUMAN CANCER-THERAPY [J].

CARTER, P ;

PRESTA, L ;

GORMAN, CM ;

RIDGWAY, JBB ;

HENNER, D ;

WONG, WLT ;

ROWLAND, AM ;

KOTTS, C ;

CARVER, ME ;

SHEPARD, HM .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (10) :4285-4289

[2] Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease [J].

Cobleigh, MA ;

Vogel, CL ;

Tripathy, D ;

Robert, NJ ;

Scholl, S ;

Fehrenbacher, L ;

Wolter, JM ;

Paton, V ;

Shak, S ;

Lieberman, G ;

Slamon, DJ .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) :2639-2648

[3] INCREASED EXPRESSION OF THE PUTATIVE GROWTH-FACTOR RECEPTOR P185HER2 CAUSES TRANSFORMATION AND TUMORIGENESIS OF NIH-3T3 CELLS [J].

HUDZIAK, RM ;

SCHLESSINGER, J ;

ULLRICH, A .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (20) :7159-7163

[4] HER-2/neu analysis in archival tissue samples of human breast cancer:: Comparison of immunohistochemistry and fluorescence in situ hybridization [J].

Lebeau, A ;

Deimling, D ;

Kaltz, C ;

Sendelhofert, A ;

Iff, A ;

Luthardt, B ;

Untch, M ;

Löhrs, U .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (02) :354-363

[5]

*ONC DRUGS ADV COM, 1998, ONC DRUGS ADV COMM 5

[6] erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer [J].

Paik, SM ;

Bryant, J ;

Park, CH ;

Fisher, B ;

Tan-Chiu, E ;

Hyams, D ;

Fisher, ER ;

Lippman, ME ;

Wickerham, DL ;

Wolmark, N .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (18) :1361-1370

[7] Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers [J].

Pegram, M ;

Hsu, S ;

Lewis, G ;

Pietras, R ;

Beryt, M ;

Sliwkowski, M ;

Coombs, D ;

Baly, D ;

Kabbinavar, F ;

Slamon, D .

ONCOGENE, 1999, 18 (13) :2241-2251

[8] Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs [J].

Pietras, RJ ;

Pegram, MD ;

Finn, RS ;

Maneval, DA ;

Slamon, DJ .

ONCOGENE, 1998, 17 (17) :2235-2249

[9]

Ryan PD, 2000, CLIN CANCER RES, V6, P4607

[10] Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. [J].

Slamon, DJ ;

Leyland-Jones, B ;

Shak, S ;

Fuchs, H ;

Paton, V ;

Bajamonde, A ;

Fleming, T ;

Eiermann, W ;

Wolter, J ;

Pegram, M ;

Baselga, J ;

Norton, L .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (11) :783-792

← 1 2 →